News on companion diagnostics and drug/test co-development.
Using its xT sequencing platform, Tempus will create a companion test to identify patients eligible for treatment with A2's cell-based LOH-targeted therapy.
The firms are focusing an initial program on the development of a companion diagnostic test for HiberCell’s immunotherapy, Imprime PGG.
On the first day, Amgen detailed the rapid advancement of its KRAS inhibitor and Tempus unveiled an AI device to help oncologists deliver precision oncology.
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.
Although a record number of new precision oncology drugs came to market, the pandemic further exposed access gaps that the field is focused on mitigating.
